In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.
Identifieur interne : 001624 ( Ncbi/Merge ); précédent : 001623; suivant : 001625In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.
Auteurs : J. Féger [France] ; E C Hirsch [France]Source :
- Annales pharmaceutiques francaises [ 0003-4509 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
Abstract
The recent medical literature highlights the lack of new drugs able to prevent or treat neurodegenerative diseases such as Alzheimer disease or Parkinson disease. Yet, the prevalence of these diseases is growing, related to increasing life expectancy, and is leading to a rise in their economic and social cost. At the same time, pharmaceutical companies are reducing or halting their investment in neuropharmacological research. Why have advances in basic neuroscience and our understanding of these diseases not allowed innovative discoveries in drug research? This review will try to explain this failure and suggest possible solutions: develop basic and clinical research but with the emphasis on translational and truly collaborative research; improve preclinical studies by developing more appropriate animal models, using new biomarkers and methodologies such as imaging suitable for clinical trials, providing worthwhile information on the ability of the drug to reach its intended target and induce significant pharmacological changes; build a new system of research management, based on stronger interdisciplinary relations between preclinical and clinical research and including the introduction of international precompetitive research between academic teams, start-up companies and pharmaceutical laboratories; hold early discussions with the regulatory authorities during preclinical studies and at the beginning of clinical trials in order to validate the methodological approaches; involve patients' associations in this new organization of research. These changes should help to ensure the discovery of effective treatments for these pathologies.
DOI: 10.1016/j.pharma.2014.10.001
PubMed: 25577012
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000419
- to stream PubMed, to step Curation: 000413
- to stream PubMed, to step Checkpoint: 000413
Links to Exploration step
pubmed:25577012Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.</title><author><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name><affiliation wicri:level="3"><nlm:affiliation>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France. Electronic address: j.feger@orange.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name><affiliation wicri:level="3"><nlm:affiliation>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France. Electronic address: etienne.hirsch@upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25577012</idno><idno type="pmid">25577012</idno><idno type="doi">10.1016/j.pharma.2014.10.001</idno><idno type="wicri:Area/PubMed/Corpus">000419</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000419</idno><idno type="wicri:Area/PubMed/Curation">000413</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000413</idno><idno type="wicri:Area/PubMed/Checkpoint">000413</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000413</idno><idno type="wicri:Area/Ncbi/Merge">001624</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.</title><author><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name><affiliation wicri:level="3"><nlm:affiliation>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France. Electronic address: j.feger@orange.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name><affiliation wicri:level="3"><nlm:affiliation>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France. Electronic address: etienne.hirsch@upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Annales pharmaceutiques francaises</title><idno type="ISSN">0003-4509</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Mental Disorders (therapy)</term><term>Neurodegenerative Diseases (therapy)</term><term>Neurology</term><term>Psychiatry</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Mental Disorders</term><term>Neurodegenerative Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Neurology</term><term>Psychiatry</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recent medical literature highlights the lack of new drugs able to prevent or treat neurodegenerative diseases such as Alzheimer disease or Parkinson disease. Yet, the prevalence of these diseases is growing, related to increasing life expectancy, and is leading to a rise in their economic and social cost. At the same time, pharmaceutical companies are reducing or halting their investment in neuropharmacological research. Why have advances in basic neuroscience and our understanding of these diseases not allowed innovative discoveries in drug research? This review will try to explain this failure and suggest possible solutions: develop basic and clinical research but with the emphasis on translational and truly collaborative research; improve preclinical studies by developing more appropriate animal models, using new biomarkers and methodologies such as imaging suitable for clinical trials, providing worthwhile information on the ability of the drug to reach its intended target and induce significant pharmacological changes; build a new system of research management, based on stronger interdisciplinary relations between preclinical and clinical research and including the introduction of international precompetitive research between academic teams, start-up companies and pharmaceutical laboratories; hold early discussions with the regulatory authorities during preclinical studies and at the beginning of clinical trials in order to validate the methodological approaches; involve patients' associations in this new organization of research. These changes should help to ensure the discovery of effective treatments for these pathologies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25577012</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>12</Day></DateCreated><DateCompleted><Year>2016</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0003-4509</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annales pharmaceutiques francaises</Title><ISOAbbreviation>Ann Pharm Fr</ISOAbbreviation></Journal><ArticleTitle>In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.</ArticleTitle><Pagination><MedlinePgn>3-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pharma.2014.10.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-4509(14)00112-6</ELocationID><Abstract><AbstractText>The recent medical literature highlights the lack of new drugs able to prevent or treat neurodegenerative diseases such as Alzheimer disease or Parkinson disease. Yet, the prevalence of these diseases is growing, related to increasing life expectancy, and is leading to a rise in their economic and social cost. At the same time, pharmaceutical companies are reducing or halting their investment in neuropharmacological research. Why have advances in basic neuroscience and our understanding of these diseases not allowed innovative discoveries in drug research? This review will try to explain this failure and suggest possible solutions: develop basic and clinical research but with the emphasis on translational and truly collaborative research; improve preclinical studies by developing more appropriate animal models, using new biomarkers and methodologies such as imaging suitable for clinical trials, providing worthwhile information on the ability of the drug to reach its intended target and induce significant pharmacological changes; build a new system of research management, based on stronger interdisciplinary relations between preclinical and clinical research and including the introduction of international precompetitive research between academic teams, start-up companies and pharmaceutical laboratories; hold early discussions with the regulatory authorities during preclinical studies and at the beginning of clinical trials in order to validate the methodological approaches; involve patients' associations in this new organization of research. These changes should help to ensure the discovery of effective treatments for these pathologies.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Féger</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France. Electronic address: j.feger@orange.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>E C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Inserm, U 1127, 75013 Paris, France; CNRS, UMR 7225, 75013 Paris, France; Sorbonne universités, UPMC univiersité Paris 06, UMR S 1127, 75013 Paris, France; Institut du cerveau et de la moelle épinière (ICM), thérapeutique expérimentale de la maladie de Parkinson, hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris cedex 13, France. Electronic address: etienne.hirsch@upmc.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Pharm Fr</MedlineTA><NlmUniqueID>2985176R</NlmUniqueID><ISSNLinking>0003-4509</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="N">Neurology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Animal models</Keyword><Keyword MajorTopicYN="N">Clinical research</Keyword><Keyword MajorTopicYN="N">Collaboration précompétitive</Keyword><Keyword MajorTopicYN="N">Drug discovery</Keyword><Keyword MajorTopicYN="N">Développement préclinique et clinique</Keyword><Keyword MajorTopicYN="N">Maladies neuropsychiatriques</Keyword><Keyword MajorTopicYN="N">Medication development</Keyword><Keyword MajorTopicYN="N">Modèles animaux</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric disorders</Keyword><Keyword MajorTopicYN="N">Organisation de recherche pharmaceutique</Keyword><Keyword MajorTopicYN="N">Precompetitive collaboration</Keyword><Keyword MajorTopicYN="N">Research management</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25577012</ArticleId><ArticleId IdType="pii">S0003-4509(14)00112-6</ArticleId><ArticleId IdType="doi">10.1016/j.pharma.2014.10.001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name></region><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001624 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001624 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25577012
|texte= In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25577012" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |